

# Effectiveness of Canadian travel restrictions in reducing burden of SARS-CoV-2 variants of concern

Angela McLaughlin<sup>1,2</sup>, Vincent Montoya<sup>1</sup>, Rachel L. Miller<sup>1</sup>, Canadian COVID-19 Genomics Network (CanCOGeN) Consortium, Michael Worobey<sup>3</sup>, Jeffrey B. Joy<sup>1,2,4\*</sup>

<sup>1</sup>British Columbia Centre for Excellence in HIV/AIDS; British Columbia, V6Z 1Y6, Canada.

<sup>2</sup>Bioinformatics, University of British Columbia; British Columbia, V5T 4S6, Canada.

<sup>3</sup>Department of Ecology and Evolution, University of Arizona; Arizona, 85721, United States.

<sup>4</sup>Department of Medicine, University of British Columbia; British Columbia, V5Z 1M9, Canada.

\*Corresponding author. Email: [jjoy@bccfe.ca](mailto:jjoy@bccfe.ca)

## Abstract

Evaluating travel restriction effectiveness in mitigating infectious disease burden is critical for informing public health policy. Here, we quantify where and when variants of SARS-CoV-2 were introduced into Canada to evaluate the extent to which travel restrictions averted viral introductions and COVID-19 case burden. Our results suggest that, across SARS-CoV-2 variants of concern subject to travel restrictions, at least 281 introductions were prevented, accounting for an averted burden of approximately 44,064 cases. This corresponds to approximately 441 averted hospitalizations, 24 averted deaths, and cost savings to Canadian health care systems of approximately 11.2 million Canadian dollars. Travel restrictions were found to be most effective when implemented rapidly during exponential case growth in the focal source and when global circulation was limited. Our analyses reveal that COVID-19 travel restrictions mitigated case burdens and highlight their value in future pandemic response.

## Summary

COVID-19 travel restrictions against variants worked and were most effective when implemented rapidly and preceding new variants' wider circulation.

## Introduction

Emergence and successive sweeps of SARS-CoV-2 variants of concern (VOCs) with elevated transmissibility, immune evasion, and/or virulence (*1*) have challenged effectiveness of COVID-19 non-pharmaceutical interventions (NPI) and vaccines. Reconstructing the emergence and spread of VOCs can illuminate NPI effectiveness in mitigating viral burden, informing policy for ongoing and future pandemics. Phylogenetic analyses of SARS-CoV-2 genomes can be applied to infer viruses' geographic and temporal origins (*2–4*), in addition to informing dynamic nomenclature systems (*5–7*), estimating key epidemiological metrics such as the effective reproduction number (*8*), and corroborating or refuting epidemiological linkage through contact tracing (*9, 10*).

Travel restrictions are a class of NPI applied to mitigate pandemic burden; they include restricted entry of foreign nationals, flight bans, border entry requirements such as testing or vaccination,

1 and quarantine requirements. Globally, evidence for their effectiveness has been mixed (11–15).  
2 Some evidence suggests countries where VOCs were first detected had diminishing contributions  
3 towards international dispersal over time, particularly those with high global connectivity, calling  
4 into question targeted travel restriction effectiveness on domestic case burden (16). Canadian  
5 COVID-19 travel restrictions were employed for travellers from regions where VOCs were first  
6 detected (**Fig. 1B** and **Supplemental Materials**), but their effectiveness in limiting introductions  
7 and case burden has not been characterized.

8  
9 Previous evidence suggested the March 2020 entry ban for foreign nationals effectively reduced  
10 viral importations into Canada, but was insufficient to prevent new SARS-CoV-2 sublineages from  
11 seeding the second wave (4). We hypothesized that subsequent Canadian SARS-CoV-2 variant-  
12 specific travel restrictions were associated with reduced introduction rates from focal sources.  
13 Second, we hypothesized that these reduced importation rates would translate into reductions in  
14 Canadian case burden, and reduced economic impacts. To test these hypotheses, we inferred  
15 phylogeographic models of SARS-CoV-2 variant dispersal into and within Canada to evaluate the  
16 effectiveness of variant-specific travel restrictions in reducing importations and averting cases. We  
17 proportionally subsampled publicly available GISAID sequences available up to March 22, 2022,  
18 after which testing frequency dropped, to estimate variant-specific cases for each Canadian  
19 province or country. We then inferred maximum likelihood phylogenetic trees for each VOC and  
20 variant of interest (VOI) and reconstructed ancestral geographies to estimate the timing, origins,  
21 destination, and spread of variants into and within Canada. We estimated the effectiveness of flight  
22 bans for Alpha, Delta, and Omicron variants, or enhanced screening for Gamma and Beta variants,  
23 in averting viral importations and cases, using a counterfactual approach, whereby expected  
24 introductions in the absence of restrictions were predicted in relation to VOC cases in focal sources  
25 and travel volume. Our findings highlight that monitoring and statistically analyzing the  
26 emergence, introduction, and spread of novel sublineages is crucially important to guide public  
27 health responses to ongoing and future epidemics.


## 28 29 **Results**

### 30 **Epidemiological synopsis of SARS-CoV-2 variants in Canada**

31 This study spans from November 2020 (2<sup>nd</sup> wave), when the first VOCs were identified in Canada,  
32 until March 2022 (5<sup>th</sup> wave), dominated by early Omicron lineages BA.1 and BA.2 (**Fig. 1**). Daily  
33 variant cases were estimated for each Canadian province by multiplying confirmed diagnoses by  
34 the frequency of variants in the GISAID database. While the 2<sup>nd</sup> wave (August 2020 – March 2021,  
35 Fig. 1) was primarily comprised of wild type SARS-CoV-2 lineages ('Other'), VOCs and VOIs  
36 gained their foothold during this time. By the 3<sup>rd</sup> wave (March 2021 – July 2021), wild type  
37 lineages were outcompeted primarily by Alpha (307,680 cases in Canada; **Table S3**), with notable  
38 contributions of Gamma (93,762 cases), Beta (18,326 cases), Eta (19,067 cases), Iota (8,325),  
39 Epsilon (5,591 cases), Zeta (2,906), Kappa (2,838), and Mu (405) across Canada, and even low-  
40 level detection of Delta lineages (first sampled in Canada on March 6, 2021). The maximum daily  
41 cases of the 2<sup>nd</sup> and 3<sup>rd</sup> waves were comparable, with the trough between the 3<sup>rd</sup> and 4<sup>th</sup> waves in  
42 summer 2021 low enough to justify relaxation of interventions. However, the 4<sup>th</sup> wave spanning  
43 August 2021 – December 2021 driven by Delta brought significant burden on the Canadian health  
44 care system with 500,617 estimated Delta COVID-19 cases. Early Omicron lineages drove a 5<sup>th</sup>  
45 wave with 630,408 BA.1 cases, 741,437 BA.1.1 cases, and 38,009 BA.2 cases cumulatively in  
46 Canada by March 22, 2022.

47

1



2


3 **Fig. 1. Epidemiological dynamics of SARS-CoV-2 variants in Canada.** (A) Estimated daily cases of variants of concern (VOC) and (VOI) in Canada from November 1, 2020 until March 22, 2022. (B) Daily variant introductions into Canada, overlaid with timing of VOC-specific travel restrictions in Canada. Introductions include sublineages, international viral introductions into Canada with sampled descendants, and singletons, international viral introductions without sampled descendants. (C) Cartoon phylogeny of SARS-CoV-2 VOCs and VOIs scaled approximately by divergence from the root.

10

### 11 **Viral introduction rate reductions from focal sources following travel restrictions**

12 VOC-specific travel restrictions were variably effective in lowering viral introduction rates from focal regions of first detection. The UK flight ban from December 20, 2020 – January 6, 2021 (duration: 17 d; delay from first sample: 44 d) in response to Alpha was associated with a non-significant 1.49 (95% confidence interval, two-sided t-distribution: 0.87-2.12)-fold reduction of the sublineage importation rate within two weeks and a 1.15 (0.91-1.39)-fold reduction of the proportion of sublineages from the UK (Figs. 2A, 3). However, the importation rate held steady amid exponentially rising Alpha cases in the UK (Fig. S23A) and then rebounded following ban repealment, rising to a maximum of 7.6 (6.3-8.8) sublineages from the UK per week on March 3, 2021. There were at least 672 (652-693) Alpha introductions into Canada, including 234 (228-240) sublineages and 438 (418-459) singletons. The UK contributed 50% (46-53%) of sublineages prior to the flight ban, 46% (39-53%) during the ban, and 37% (35-40%) after (Fig. S30). Altogether, 40% (38-42%) of sublineages and 45% (43-48%) of singletons originated in the UK (which represented 20% of international sequences), followed by Europe, the origin of 31% (29-

1 32%) of sublineages and 23% (21-25%) of singletons, and the USA, contributing 23% (22-24%)  
 2 of sublineages and 26% (25-28%) of singletons.  
 3



4 **Fig. 2. VOC sublineage introduction dynamics into Canada in the context of COVID-19**  
 5 **travel restrictions.** The 7-day rolling average weekly sublineage introduction rates were inferred  
 6 using maximum likelihood phylogeography for (A) Alpha, (B) Beta, (C) Gamma, (D) Delta, and  
 7 (E) Omicron, BA.1 and (F) BA.1.1. Most introductions of Omicron BA.2 came after travel  
 8 restrictions and thus BA.2 was excluded here. Global regions contributing most sublineages were  
 9 directly annotated. 95% confidence intervals across 10 bootstraps for focal regions of first VOC  
 10 detection are displayed and additionally for the USA for BA.1 and BA.1.1. Travel restriction  
 11 durations for each variant shown with shaded grey rectangles.  
 12

13  
 14 For Beta, enhanced screening and quarantine enacted for travellers who had been to South Africa,  
 15 effective December 24, 2020 - February 22, 2021 (duration: 60 d; delay from first sample: 5 d),  
 16 was associated with a significant 6.25 (2.72-9.78)-fold reduction of the Beta sublineage  
 17 importation rate from South Africa, as well as a 1.75 (1.33-2.18)-fold reduction of the proportion  
 18 of sublineages from South Africa (Figs. 2B, 3). During the restriction, there was a rise in Beta  
 19 sublineages likely to have originated in Europe and other African nations; following restrictions,  
 20 Beta importations from Asia increased. Overall, of 40 (40-41) total estimated sublineages, 14%  
 21 (12-16%) were likely from South Africa, 31% (30-33%) from Asia, and 20% (18-22%) from other  
 22 African nations (Fig. S39). Of 80 (77-83) total singletons, 8% (7-9%) were likely from South  
 23 Africa, while 41% (39-42%) were from Asia, 22% (19- 24%) from Europe, and 18% (17- 20%)  
 24 from other African nations.  
 25

1 Neither of the Gamma-related restriction periods with enhanced screening for travellers from  
2 Brazil was associated with significant reduction in sublineage importations from Brazil into  
3 Canada (**Figs. 2C, 3**). The second period of restrictions from March 30 to April 14 (duration: 15  
4 d) was associated with a significant 1.6 (1.27-1.93)-fold reduction in the proportion of sublineages  
5 from Brazil; however, the number of Gamma sublineages observed during this period (n=3) was  
6 relatively low. Brazil was the likely origin for 52% (50–55%) of the 38 (37-40) Gamma  
7 sublineages in Canada, while the USA accounted for 29% (26-32%), other South American nations  
8 for 12% (10-14%), and other North American nations for 6% (5-8%) (**Fig. S33**). Of 159 (148-170)  
9 total Gamma singletons, 65% (63-67%) were likely from Brazil.

10  
11 Suspension of flights from India to counter the Delta variant from April 22, 2021 to September 26,  
12 2021 (duration: 157 d; delay from first sample: 47 d) was associated with a significant 2.4 (1.8-  
13 3.0)-fold reduction of the sublineage importation rate from India within two weeks and 7.5 (4.6-  
14 10.4)-fold within four weeks from a maximum of 19.0 (17.5-20.5) sublineages per week on April  
15 24 (**Fig. 2D**). The singleton importation rate from India was also significantly reduced (**Figs. 3,**  
16 **S45**). By late June 2021, Delta sublineage importation from the USA and Europe superseded India,  
17 and for the USA in particular, continued to rise to a maximum of 20.7 (16.8-24.6) sublineages per  
18 week on December 4, 2021. There were at least 1822 (1794-1850) Delta introductions into Canada,  
19 including 537 (521-553) sublineages representing 90 (86-93) unique Pango lineages, and 1285  
20 (1253-1317) singletons. The flight ban was additionally associated with a 3.8 (3.6-4.1)-fold  
21 reduction in the proportion of sublineages originating from India (**Fig. 3**). Prior to the restriction,  
22 95% (93-97%) of 76 (72-80) Delta sublineages were from India, compared to 25% (23-26%) of  
23 228 (218-237) sublineages introduced during the restriction (**Fig. S43**). After the flight ban, 233  
24 (225-240) additional sublineages were introduced, primarily from the USA, Europe, and with a  
25 lesser contribution from India. Overall, the USA was the likely origin for 48% (47-49%) of Delta  
26 sublineages and 50% (49-52%) of singletons, followed by India for 26% (25-27%) of sublineages  
27 and 21% (20-22%) singletons, and then Europe for 19% (18-20%) of sublineages and 20% (19-  
28 21%) of singletons (**Fig. S44**). India and the USA accounted for 15% and 42%, respectively, of  
29 global sequences sampled. The flight ban was also associated with a reduction of sister lineage  
30 Kappa (B.1.617.1) sublineage and singleton importation rates from India (**Fig. S42**).


31  
32 The Omicron-related entry ban for foreign nationals arriving from southern African nations and  
33 enhanced screening for Canadians who had been to southern Africa (duration: 22 d) was largely  
34 ineffective towards reducing importations of BA.1 and BA.1.1. No BA.2 was known to have been  
35 introduced prior to the travel restrictions; therefore, we cannot comment upon the effect travel  
36 restrictions may have had on BA.2 introductions to Canada. The flight ban was not significantly  
37 associated with a reduction in the BA.1 or BA.1.1 sublineage importation rates from southern  
38 Africa two weeks following the restriction (1.7 (0.2-3.2)-fold reduction in BA.1 and 0.49 (-0.03 -  
39 1)-fold reduction in BA.1.1; **Figs. 2E-F, 3**). There was a significant 2.4 (1.3-3.6)-fold reduction in  
40 the proportion of BA.1 sublineages from southern Africa following the ban, which changed from  
41 3% (1-5%) of sublineages with southern African origins before restrictions to 1% (1-2%) during  
42 restrictions (**Fig. S50**); however, this coincided with increased importation rates from the USA,  
43 reaching a maximum of 74.2 (71.0-77.4) BA.1 sublineages per week on December 17, 2021 (**Fig.**  
44 **2E**). There was no significant reduction (1.75-fold reduction, 0.4-3.1) in the proportion of BA.1.1  
45 sublineages from southern Africa two weeks following restriction implementation. Before, during,  
46 and after the restrictions, BA.1.1 sublineages in Canada predominantly originated from the USA,

1 which was the source of up to 128.2 (114.9-141.6) sublineages per week on December 21, 2021  
 2 (Fig. 2F). By contrast, the maximum flow of BA.1.1 from southern Africa was 0.93 (0.1-1.76)  
 3 BA.1.1 sublineages per week on November 18, 2021 and 1.8 (0.9-2.7) BA.1 sublineages per week  
 4 on December 3, 2021. The USA was the predominant source of Omicron BA.1 and BA.1.1 into  
 5 Canada up to March 2022, contributing 72% (70-73%) of 615 (596-633) BA.1 sublineages (Fig.  
 6 S50), 90% (89-91%) of 1148 (1103-1194) of BA.1.1 sublineages (Fig. S51), 74% (73-75%) of  
 7 3634 (3524 - 3744) BA.1 singletons, and 92% (91-93%) of 5572 (5337 - 5806) of BA.1.1  
 8 singletons. Africa and South Africa combined likely contributed 1% (1-2%) of BA.1 sublineages,  
 9 <1% BA.1.1 sublineages, 2% (1-2%) of BA.1 singletons, and <1% BA.1.1 singletons.  
 10 Predominant sources of early BA.2 introductions were India and the UK, and negligibly few BA.2  
 11 introductions originated from the USA or Africa (Fig. S52). Sequences from the USA represented  
 12 40% of international sequences subsampled for BA.1 and 66% for BA.1.1; i.e., USA introductions  
 13 exceeded what would be expected by chance.

14

15 Comparing VOCs according to fold-reduction in sublineage importations (Fig. 2, 3), Delta and  
 16 Beta restrictions were associated with significant reductions in sublineage importation rate from  
 17 focal sources 2- and 4-weeks following implementation and the proportion of sublineages from  
 18 the focal source. However, Beta restrictions were not associated with significant reductions in  
 19 singleton rates from South Africa, and estimates have wide uncertainty due to rare events. The  
 20 second Gamma intervention was associated with significant reductions in singleton importation  
 21 rates from Brazil 2- and 4-weeks after implementation, but not sublineage importation rate. The  
 22 Delta-related India flight ban was associated with significant reductions in both absolute and  
 23 relative sublineage and singleton contributions from India to Canada within two and four weeks  
 24 of implementation. However, these reductions in importations were eventually eclipsed by the  
 25 influx of sublineages from the USA and other countries not specified in the respective travel  
 26 restrictions.

27



28

29 **Fig. 3. Comparison of fold-reduction in VOC importations from focal sources following**  
 30 **travel restrictions.** Metrics include fold-reduction of the 7-day rolling average sublineage  
 31 importation rates or singleton importation rates from focal sources two and four weeks after  
 32 restrictions began; and fold-reduction of the proportion of sublineages or singletons originating  
 33 from focal sources before versus during travel restrictions. Diamonds show the mean and vertical  
 34 lines depict 95% confidence interval across ten bootstraps. Estimates were not shown where  
 35 comparisons included a zero. Dotted line at  $y=1$  represents the null expectation of no change.

## 2 **Introductions and cases averted via VOC travel restrictions**

3 We applied counterfactual models relating introductions to variant cases in focal sources to  
4 quantify how many sublineages, singletons, and cases were averted due to travel restrictions.  
5 Averted travellers were estimated based on epochal and seasonal trends in international air arrivals  
6 (**Supplementary Methods**).

7  
8 In the absence of the UK flight ban, we estimated there were likely to have been 724 additional  
9 travellers from the UK, 12 (9-16) additional Alpha sublineages that could have resulted in upwards  
10 of 5,682 (3,849-7,132) descendant cases, as well as 58 (44-73) singletons (**Fig. 3A**). The ban  
11 became more effective over time as daily Alpha cases in the UK rose during the latter part of the  
12 flight ban (**Fig. S23**). Significantly more sublineages, singletons, and cases were averted per day  
13 in the late period (December 28, 2020 – January 6, 2021) versus early period (December 20-27,  
14 2020), with over three times as many sublineages averted per day in the late period (**Fig. 4**). In  
15 totality, these 5,740 (3,893-7,205) averted cases represent an additional 1.8% (1.2-2.2%) of all the  
16 324,547 estimated Alpha cases detected in Canada. When normalized to the restriction duration of  
17 17 days, an average of 338 (229-424) cases were averted per day during the UK flight ban; which  
18 for the late period was even higher at 482 (380-637) cases averted per day.

19  
20 Enhanced screening for travellers from South Africa countering the Beta variant averted only 3  
21 travellers, 5 (0-10) Beta sublineages, and 1 (-4-6) singletons (**Fig. 4**). Consistent with Alpha, the  
22 early (24 December 2020 – 21 January 2021) and late (22 January – 22 February 2021) periods of  
23 the ban displayed contrasting dynamics, although for Beta, effectiveness lessened. The early period  
24 was associated with 9 (6-11) averted sublineages that could have resulted in 1,645 (1,551-1,739)  
25 descendant cases, while the late period was associated with -4 (-6--2) averted sublineages (more  
26 observed than expected in the absence of the ban). Assuming their conservative net sum of 5 (0-  
27 10) sublineages averted, there were 1,019 (0-2,111) descendant cases averted. These averted cases  
28 would have represented an additional 8.2% (0-16.2%) of the 12,462 total estimated Beta cases in  
29 Canada (**Fig. 3B; Fig. S24**). The average effectiveness for Beta was relatively low at 17 (0-34)  
30 cases averted per day, but the late period may have averted up to 59 (44-79) cases per day.

31  
32 Initial enhanced screening for travellers from Brazil countering Gamma averted more travellers,  
33 introductions, and cases than the second intervention period (**Fig. 4; Fig. S25**). The first  
34 intervention averted 326 travellers, 4 (3-6) sublineages that may have given rise to 7,932 (4,081-  
35 9,839) descendant cases, and 4 (-15-22) singletons. Averted sublineages during the first period had  
36 a relatively high probability of being large based on the right-skewed distribution of observed  
37 Gamma sublineage sizes until the end of restrictions. 7,935 (4,066-9,862) total averted cases  
38 during the first intervention represents an additional 7.4% (3.8-9.2%) of the estimated Gamma  
39 cases in Canada, and an average effectiveness of 209 (107-260) cases averted per day. The second  
40 intervention period was less effective, likely averting 58 travellers, -1 (-2-0) sublineages, and 2 (-  
41 3-7) singletons.


42  
43 The India flight ban was effective in averting many travellers, sublineages, singletons, and cases,  
44 however it diminished in effectiveness as Delta cases increased globally (**Fig. 4**). Over five  
45 months, the ban likely averted 5,148 travellers from India. The number of daily travellers averted  
46 was steadily high from late April to mid-June 2021, dropping in July 2021 before becoming erratic

1 with rising travel volume via other countries, which was permitted with a negative PCR test  
2 (**Figures S19**). 63 Delta sublineages were observed during restrictions, whereas we predicted there  
3 would have been 259 (237-280) sublineages imported without restrictions, amounting to 196 (174-  
4 217) Delta sublineages averted throughout the entire flight ban (**Fig. S26**). There were more  
5 sublineages averted in the first period of the ban up to the end of June (2 (2-2) sublineages averted  
6 per day) compared to July through September when the ban ended (1 (1-1) sublineages averted per  
7 day). Averted sublineages could have given rise to 25,935 (22,431 – 29,891) cases. An additional  
8 525 (338-711) singletons were averted or 3 (2-5) singletons averted per day. More singletons were  
9 averted in the first period of the ban, 6 (5-7) per day, versus the second period, with 1 (0-2) per  
10 day. In totality, 26,460 (23,474-29,819) cases were likely averted. Relative to the 491,733 total  
11 estimated Delta cases in Canada, this would have represented 5.4% (4.8-6.1%) additional sampled  
12 Delta cases. Overall, 165 (147-186) cases were averted per day during the Delta ban; in the first  
13 period, 252 (232-271) cases were averted per day, which decreased to 99 (83-116) in the second  
14 period. We were unable to test the effectiveness of the two-month flight ban for Pakistan because  
15 the sequence representation was low enough to warrant its grouping with Asia; however, we  
16 estimated 116 travellers from Pakistan were averted (**Fig. S22**).

17  
18 For Omicron, the entry ban for foreign nationals and enhanced screening for Canadians who had  
19 travelled to southern Africa nations was largely ineffective in reducing Omicron burden (**Fig. 4**).  
20 Although it may have averted 1,681 travellers from Africa, 4 (2-6) BA.1 and 8 (6-11) BA.1.1  
21 sublineages, as well as 1,607 (823-2349) BA.1 cases and 1,838 (1364-2247) BA.1.1 cases, these  
22 were negligible compared to the massive burden of Omicron. The cases averted by southern Africa  
23 entry restriction represented only 0.3% (0.1-0.4%) of 634,334 BA.1 cases and 0.2% (0.2-0.3%) of  
24 779,903 BA.1.1 cases confirmed by March 10, 2022. Overall intervention effectiveness was 73  
25 (37-107) BA.1 and 84 (62-102) BA.1.1 cases averted per day. The second period of the  
26 intervention was more effective than the first period of the intervention at 161 (82-198) BA.1 cases  
27 and 137 (93-184) BA.1.1 averted per day. Omicron cases per day in South Africa and other African  
28 nations were higher in the second period of the intervention than the first (**Fig. S27, S28**). We did  
29 not find any evidence of BA.2 sublineages introduced from either South Africa or Africa, and only  
30 one singleton which likely was introduced in mid-February (**Fig. S53**).

31  
32 Overall, variant-specific restrictions were variably effective, but conservatively may have averted  
33 at least 281 introductions and 44,064 additional cases in Canada. The majority of cases averted  
34 were Delta (25,922), followed by Gamma (7,937 v), Alpha (5,740), Omicron BA.1.1 and BA.1  
35 (3,445), and Beta (1,020). The restrictions that averted the highest percentage of cases relative to  
36 the variant case burden observed in Canada were Beta (8.2%, with the caveat of wide uncertainty  
37 and relatively low burden), the first Gamma intervention (7.4%), Delta (5.3%), Alpha (1.8%), and  
38 lastly, Omicron BA.1 (0.3%) and BA.1.1 (0.2%). Comparing restrictions' effectiveness in terms  
39 of cases averted per day, Alpha was the most effective (338 per day), followed by the first period  
40 of Delta (252 per day), the first Gamma intervention (209 per day), and Omicron BA.1 and BA.1.1  
41 (157 per day).





1  
2 **Fig. 4. Averted introductions and cases attributable to VOC travel restrictions.** Sublineages,  
3 singletons, and estimated cases averted overall and normalized to intervention duration;  
4 and percent additional cases averted relative to total variant cases in Canada. Metrics were estimated  
5 for entire intervention and for early and late periods of the intervention. Gamma interventions were  
6 considered only separately.

7  
8 Based on cases averted, average COVID-19 hospitalization and death rates, and estimated public  
9 healthcare cost of a COVID-19 patient in Canada, we conservatively estimated averted  
10 hospitalizations and deaths, and corresponding costs averted. Between May 2020 and April 2021,  
11 the average COVID-19 hospitalization rate in the USA was estimated as 1093.9 per 100,000  
12 (1.1%) (17). Therefore, without considering differences in variant virulence or age demographics,  
13 we coarsely assume 1% of COVID-19 cases averted could have been hospitalized. The average  
14 cost per COVID-19 patient hospitalization in Canada was \$15,000 for those not in ICU and

1 \$55,000 for those admitted to ICU, with financial information up to May 2023 (18). Across data  
2 up to March 2022, 21% of hospitalized COVID-19 patients were admitted to the ICU (18), of  
3 whom 56% received ventilation and 25% died in the facility. Correspondingly, approximately 441  
4 COVID-19 hospitalizations were averted, of which 93 may have been admitted to ICU, and 24  
5 may have died. The cumulative medical cost of these averted instances is approximately  
6 \$11,214,364 Canadian dollars (CAD). We do not consider the additional costs (and suffering)  
7 incurred by families and friends, funeral and estate costs, or diminished economic activity due to  
8 employee absences.

## 9 **Discussion**

10 Our findings suggest that Canadian COVID-19 travel restrictions were variably effective towards  
11 reducing SARS-CoV-2 VOC importations and cases, but cumulatively may have averted more  
12 than 280 introductions, 44,000 cases, 440 hospitalizations, and 24 deaths; conservatively  
13 corresponding to an estimated savings greater than \$11.2 million CAD. We developed a novel  
14 methodology to estimate introductions and cases averted which applies a counterfactual model  
15 considering estimated variant cases in focal origins, travel volume, and their empirical  
16 relationships with introductions into Canada. This enabled us to both quantify the overall  
17 effectiveness of interventions on case burden, but also quantify effectiveness over time, providing  
18 retrospective insights into when restrictions could have ended.

19  
20  
21 The India flight ban against Delta introductions was the most effective restriction, corresponding  
22 to a large decline in the importation rate from India and averting over 30,000 additional cases.  
23 However, the ban's effectiveness decreased past June 2021, after which Delta cases and  
24 importations from the USA and other countries rose and cases in India decreased. Regionally  
25 coordinated policy towards the Delta lineage by Canada, USA, and other high volume travel hubs  
26 may have led to further durability in travel restriction effectiveness. Other analyses of Delta  
27 transmission dynamics in Canada found early introductions of AY.25 and predecessor of AY.27  
28 (which may have arisen in Canada) drove Delta burden in Canada, corroborating the futility of  
29 later stages of the flight ban (19). Repeated extension of the India flight ban was unnecessary past  
30 June 2021, although was likely guided by the precautionary principle due to concerns related to  
31 case underreporting and Delta's elevated virulence and transmissibility (20–22). The ban should  
32 have been implemented earlier and relaxed earlier in light of evidence that Delta was globally and  
33 domestically widespread.

34  
35 Our results suggested the UK flight ban targeting Alpha increased in effectiveness as cases  
36 climaxed in the UK, while the Beta enhanced screening for South Africa and Gamma enhanced  
37 screening for Brazil became less effective over time and were potentially leakier. Omicron-  
38 targeted southern Africa entry bans were largely unsuccessful in reducing importations or case  
39 burden, as BA.1 and BA.1.1, followed by BA.2, BA.4, and BA.5, were introduced via other global  
40 sources. In instances where the proportion of sublineages from an area was reduced following  
41 travel restrictions, but the sublineage importation rate was not significantly reduced, the  
42 interpretation is that there the travel restriction had a minor effect. When a new variant has emerged  
43 and global regions have similar case trajectories and stable relative travel volumes, then the  
44 proportion of introductions should remain constant in the absence of restrictions or if restrictions  
45 were entirely ineffective. Where the sublineage importation rate and proportion of sublineages  
46 decrease in association with travel restrictions, there is a major effect, particularly if cases were

1 rising in the region targeted by the restriction. The counterfactual approach we have taken allowed  
2 us to take into consideration variant cases and travel in the targeted nations to predict sublineage  
3 importation rates without restrictions.  
4

5 Globally, evidence relating to travel restrictions' effectiveness in reducing COVID-19 burden is  
6 mixed. Several reviews on the topic highlight a lack of consensus in methodologies for empirically  
7 evaluating COVID-19 interventions' effectiveness, including different definitions or criteria for  
8 effectiveness (11, 12, 23). In United Arab Emirates, a decline of transmissions from international  
9 sources followed implementation of international travel restrictions in 2020 (14). In Zimbabwe,  
10 initial public health interventions delayed onset of community transmission following international  
11 introduction during the first waves of COVID-19 (24). The implementation of international travel  
12 restrictions and stringent domestic interventions within a zero-COVID policy until the end of 2021  
13 in New Zealand eliminated community transmission until the arrival of the Delta variant (21).  
14 Other studies found intermediate effectiveness, such as in South Korea, where international  
15 traveler quarantine in 2020 reduced introductions and spread of SARS-CoV-2, but control was  
16 incomplete (25). Mandatory hotel quarantines in response to the Delta variant reduced onward  
17 transmission of Delta importations in England, but subsequent NPI relaxation drove rapid  
18 transmission of early introductions (26). As for evidence of low effectiveness, restriction of travel  
19 from Brazil to the USA did not prevent establishment of the Gamma variant in New York City, as  
20 the majority of Gamma transmission lineages had already been established at least two weeks prior  
21 originating from other regions in the USA (13). In Hong Kong, border control measures were  
22 deemed insufficient to prevent outbreaks, especially during a period of lower stringency of social  
23 restrictions (15). While this by no means comprises a comprehensive review of evidence, these  
24 examples highlight the lack of consensus regarding how to measure effectiveness and consider the  
25 epidemiological circumstances in which a measure was enacted. What can be distilled from this  
26 body of work is that, as implemented, travel restrictions do not stop all introductions, but they can  
27 reduce the flow, and their impact depends upon the epidemiological, immunological, and  
28 stringency context in which they are invoked, as well as their coordination with neighboring  
29 countries.  
30

31 Many factors can impact travel restriction effectiveness and should be weighed at the time of  
32 implementation. Of first consideration are the magnitude and rate of change in prevalence in the  
33 country where a variant is first detected, as well as in other geographies that could act as sources.  
34 Additionally, importations and cases were most effectively averted when restrictions were  
35 implemented rapidly. Part of the reason the Omicron ban may have been less effective is that it  
36 was discovered on November 19, 2021, over a month following its estimated origin around  
37 October 9, 2021 (27). By the time restrictions were implemented for travel from southern Africa,  
38 Omicron had already dispersed globally, and the USA was a dominant early exporter of BA.1  
39 globally (16). The Delta-related flight bans commenced 47 days after the first Delta case was  
40 sampled in Canada, and Beta-related measures began 5 days after first detection. The extent of  
41 variant spread during this delay is affected by the focal geographies' global travel volume and  
42 degree of connectedness (16), as well as a variant's inherent transmissibility. Another factor is a  
43 variant's antigenic distance and immune evasion potential, which in combination with  
44 immunological waning from natural infections and vaccines, determine the extent of population-  
45 level susceptibility and thus potential for introductions to become large outbreaks. Outbreak sizes  
46 can also be minimized in the presence of domestic NPIs, such as restrictions on social gathering

1 or mask requirements that reduce contact rates or transmission probabilities, and higher  
2 compliance. Legal and logistical travel loopholes could compromise restriction effectiveness by  
3 increasing border porosity. For the Delta-related flight bans, there was a loophole whereby  
4 travellers from India and Pakistan could enter Canada indirectly through intermediary flights, but  
5 were required to present a negative COVID-19 test upon arrival (28). Travel volume from India  
6 expanded during later stages of the ban (**Fig. S14**). Variant virulence and rates of hospitalizations  
7 and deaths are also important to consider for overall health care burden.

8  
9 There are multiple sources of uncertainty and limitations in this analysis. Publicly available  
10 genome sequences and confirmed diagnoses over time are affected by differences in case  
11 ascertainment across geographies, time, variants, case severity, and sociodemographic groups.  
12 Therefore, daily new diagnoses based on PCR confirmed positive cases do not equate to daily new  
13 infections. Within any given jurisdiction, there were changes in frequency of symptomatic  
14 infection and hospitalization, testing criteria and public health recommendations, testing capacity,  
15 and availability of rapid antigen tests (for which results were not always reported). One way to  
16 consider changes in age-based testing criteria is to associate fluctuations in case counts among the  
17 widely tested 70+ age group, for which testing recommendations did not change in late 2021, with  
18 cases in other age groups (29). However, this approach fails to consider differential changes in  
19 behaviour and social contact across age groups in response to the pandemic, as well as does not  
20 consider other sources of ascertainment bias affecting all age groups. In addition to case  
21 ascertainment bias, jurisdictions varied in extent and reason for sequencing, as well as in their  
22 proclivity to share this data publicly. When analyzing empirical sequence data sets, where reason  
23 for sequencing could be due to hospitalization, association with an outbreak, travel history, or  
24 variant suspicion (spike gene target failure requiring variant confirmation, for example), we must  
25 interpret frequencies cautiously. An idealized surveillance strategy would be to longitudinally  
26 surveil a randomly selected cohort for infection (regardless of symptoms) with all cases sequenced,  
27 which would yield accurate estimates of the percent positivity (prevalence), variant frequencies,  
28 and levels of re-infection in the wider community. Accurate case counts are important to quantify  
29 burden, as well as to inform sequence subsampling strategies to minimize bias.

30  
31 Accuracy of phylogeographic inferences has been shown to be high when the migration rate is  
32 low, however sampling differences across jurisdictions can contribute to biases (30). We  
33 developed a sequence subsampling strategy to reduce sampling bias in the publicly available  
34 sequence data, while also rendering the analysis computationally feasible for maximum likelihood  
35 phylogenetic inference. With moderately large subsamples of 50,000 sequences, regions that  
36 contributed high sequences per case were less overrepresented, but regions with few sequences  
37 available relative to cases remain underrepresented. With smaller subsamples, the ratio of  
38 sequences to cases can be more normalized but this reduces the data informing the model, and thus  
39 it is a fine balance of maximizing signal while ensuring representativeness. Differences in reason  
40 for sequencing are also not alleviated via subsampling. Future developments in subsampling and  
41 phylogeographic methodologies could profit from structured consideration of reason for  
42 sequencing, as well as carrying forward sampling proportion or case ascertainment in the  
43 phylogeographic inference. Recent methodological developments to include unsampled nodes in  
44 phylogeographic inference are promising, but are at present, not scalable to tens of thousands of  
45 sequences (31).

1 Inclusion of 50% Canadian and 50% global sequences in each subsample was based upon findings  
2 from previous sensitivity analyses, whereby this relative representation identified the maximum  
3 number of sublineages and singletons (4). Additionally, the 50% split imposes a prior expectation  
4 that any given sequence from Canada is equally likely to have a close relative from either Canada  
5 or global. One might ask, if we are interested in quantifying primarily introduction dynamics from  
6 focal sources, why not include more sequences from the focal source relative to other global  
7 regions? Doing so would increase the chance of misattributing the origin of a sublineage to the  
8 focal source when it could have come from a different country. While the focus is on the dynamics  
9 of the focal source sublineage importation rate, contributions from other regions remain important.  
10 By treating the focal source equally to other global regions at the subsampling stage, we do not  
11 impose a bias towards the focal source in the ancestral reconstruction; thus, our estimates represent  
12 lower bounds of sublineages per week, but proportionally and temporally, should be accurate. By  
13 subsampling multiple bootstraps with replacement, we considered how the relative inclusion of  
14 sequences and geographies affect uncertainty in our estimates of importations and sublineage sizes.  
15

16 In addition to uncertainty as to whether sequence sets were representative of the pandemic in  
17 Canada and globally, there was also uncertainty due to phylogenetic tree inference, time-scaling  
18 the tree under a relaxed molecular clock model, and ancestral character estimation of geographic  
19 origins. For 50,000 tips, it is impossible to search the entire tree space for the most likely tree,  
20 therefore the trees analyzed represent local maxima. Furthermore, this pipeline requires scaling  
21 trees from units of divergence to time, which presupposes a molecular clock rate can be generalized  
22 for the tree. Even though a relaxed molecular clock rate was assumed with no fixed mean, a prior  
23 variance of 0.2 across the tree was assumed, which could misrepresent the underlying evolutionary  
24 process. By partitioning tree inference by variant with a small subset of parental lineage sequences,  
25 we have partially accounted for differences in molecular clock rates across variants, including  
26 during their emergence. Tip dates inform rescaling the tree, but themselves can be speckled with  
27 errors, for instance due to delay between infection and sampling, data entry errors, and in some  
28 cases, incomplete metadata collection dates. Incomplete dates in the Canadian metadata were dealt  
29 with by randomly sampling from potential days. This added some uncertainty to the analysis,  
30 particularly in regards to the timing of sublineage introduction dates. Incomplete dates in metadata  
31 associated with Canadian samples from particular regions were an ongoing issue despite calls for  
32 public access to full data to enable genomic epidemiological surveillance (32–34). In previous  
33 analyses for the first two waves of SARS-CoV-2, incomplete tip dates were inferred using least  
34 squares dating (35), which slowed the time-scaling of trees and in some cases was intractable due  
35 to insufficient memory.  
36

37 A comprehensive understanding of how variant dynamics were impacted by travel restrictions  
38 requires consideration of changes in the environment, host, and virus. Human behavioral changes  
39 relating to contact networks and transmission probability via other non-pharmaceutical  
40 interventions should be considered in relation to any detected changes in transmission. Further,  
41 heterogeneity in population-level immunity due to vaccination and infection confound our ability  
42 to identify changes in sublineage characteristics, such as transmissibility or lifespan. Disentangling  
43 the effects of public health interventions from viral genetic adaptations in regards to migration,  
44 transmission, and health care burden is a formidable challenge. VOCs vary in their selective  
45 advantages to outcompete previously circulating diversity (36), which we have not explicitly  
46 considered in these models. This was indirectly considered by stratifying variants in the analysis.

1 Methodological developments on estimating variant-specific reproduction numbers and fitness  
2 advantages offer some promise in this regard (37). Of course, as with all models, we have  
3 endeavoured to infer sufficiently complex models with as few assumptions as possible while  
4 maintaining generalizability. Further developments in bridging phylogeographic inference with  
5 mathematical modelling could be fruitful in this regard (38).

6  
7 We applied travel volume data in our phylogeographic methods by using it to adjust our null  
8 expectation of travel volume from a given country if there had not been a travel restriction imposed  
9 on that country. By considering seasonal and epochal changes in travel volume into Canada, we  
10 estimated travel volume in the absence of restrictions and travellers averted. This approach  
11 considers broad changes in propensity or ability to travel, considering discovery of new variants  
12 or changes in vaccination and testing requirements. Although we attempted to adjust models  
13 relating sublineage flows to variant cases by travel volume, in practice, these models only  
14 improved the goodness-of-fit for the BA.1 model. Further explorations of travellers compared to  
15 importations averted are warranted. Another way to use flight data is to model exportation  
16 intensities from different regions as the product of the estimated number of infected people in a  
17 given geography at a given time by travel volume into a country of interest. This has been applied  
18 in place of inferring transmission lineages' origin locations when introductions were identified  
19 using binary state ancestral reconstruction (3). Another way to use flight data is to investigate  
20 whether phylogeographically inferred importation rates are consistent with expected importation  
21 intensities. When available, individuals' travel history can also be used as priors in in travel-aware  
22 phylogeographic models (31).

23  
24 The questions facing the global community to respond to and learn from SARS-CoV-2 have  
25 evolved, as have the methodologies used to approach these questions (39). Combining  
26 phylogenetics, mathematical modelling, and machine learning could improve the accuracy of  
27 infectious disease forecasting (38). For instance, phylogenetics offer insight into taxonomic  
28 groupings for model structuring, estimates of migration rates, and evolutionary rates, which can  
29 be incorporated into compartmental models. Models would also benefit from improved variant-  
30 specific estimates of selection in the context of vaccine- and natural infection-induced immunity.  
31 Longitudinal prospective cohort studies of generalizable populations (i.e., not just those above the  
32 age of 70) would be helpful in estimating frequencies of circulating variants or sublineages,  
33 positivity rates, period of infectiousness, incidence, and the true sampling rate. Accurate  
34 estimations of case ascertainment and relatedly, sampling rates, in the broader population might  
35 be estimated compositely from knowledge for specific variants of the difference between expected  
36 percent positivity from the cohort vs observed in broader data, as well as knowledge of reason for  
37 sequencing in the publicly available data.

38  
39 However, we have provided evidence that they reduce the flow of pathogens across borders,  
40 particularly when implemented rapidly following initial detection. In instances where viral  
41 establishment is nearly inevitable, travel restrictions can contribute to flattening the curve to  
42 mitigate the burden on the health care system with limited finite resources. If a government adopts  
43 a travel restriction policy to limit burden, we recommend simultaneously adopting other NPI  
44 domestically, like installing adequate ventilation and promoting mask use, to prevent introductions  
45 from becoming widespread sublineages.

1 Travel restrictions to curb importations from countries where variants are first detected should be  
2 considered alongside other public health interventions when sufficient evidence suggests there is  
3 a high risk to individual- and population-level human health; equally, they should be repealed if  
4 there is strong evidence that the variant is already established or poses a low risk to health.  
5 Formalizing coordination among neighboring jurisdictions would increase the odds of successful  
6 restrictions. Sustained investment in developing genomic surveillance systems, including in  
7 wastewater, cohort surveys, and in wildlife, will enable rapid detection and monitoring of  
8 circulating variants. Ongoing deposition of anonymized pathogen sequence data into the public  
9 repository, with time and date of sampling, is important to facilitate genomic epidemiology studies.

## 10 11 **Conclusion**

12 We have presented robust and novel methods for quantifying effectiveness of public health  
13 interventions in reducing pathogen introductions and averting cases, which can contribute to the  
14 evidence base considered for future implementation and policy. Ongoing funding and  
15 prioritization of viral genomic surveillance programs in humans and the animals will help to  
16 mitigate future pandemic threats and curtail the ongoing burden of the COVID-19 pandemic.  
17 Without global surveillance, we do not know how widely a variant has spread or how quickly it is  
18 spreading, limiting our ability to confidently react to the emergence of new variants or pathogens.

19  
20 We conclude by emphasizing that it is critical to consider that travel restrictions can and have had  
21 very negative socioeconomic impacts. As such, they provide a strong disincentive to countries that  
22 are first to detect new SARS-CoV-2 variants of concern to make those discoveries public. This  
23 issue is one that we expect to continue as new subvariants and perhaps entirely new variants of  
24 SARS-CoV-2 emerge through time. Even more concerningly, these disincentives can be predicted  
25 to contribute to hesitation (or complete reluctance) to report future emerging pathogens on the part  
26 of countries first to detect them, likely the countries where they originated. This may contribute to  
27 the loss of a window of opportunity to prevent a potential new pandemic from being actualized.  
28 The scientific evidence presented here that travel restrictions can have public health benefits needs  
29 to be viewed in that larger context.

## 30 31 **Methods**

### 32 **Sequence data sets and curation**

33 9,487,106 SARS-CoV-2 sequences and associated metadata (298,892 collected in Canada) were  
34 downloaded from Global Initiative on Sharing All Influenza Data (GISAID) on March 22, 2022  
35 (40, 41). GISAID clade partitions were maintained throughout data cleaning to reduce  
36 computational burden. Sequences were excluded if they were listed on the Nextstrain exclude list  
37 updated on day of data download (n=8,782) (7, 42), duplicate IDs (n=4,284), from a non-human  
38 host (n=6,803), environmental samples (n=4,907), or had incomplete dates outside of samples  
39 from Canada (n=218,233). For Canadian sequences with incomplete dates, days were randomly  
40 sampled within known months. If only year was provided, the sequence was discarded.

41  
42 Sequences were aligned to Wuhan-Hu-1 (GenBank ID: MN908947.3) using the viralMSA python  
43 wrapper of minimap2 (43, 44). Sequences were excluded if ambiguous sites or gaps exceeded 10%  
44 (n=7,968 and n=657,063, respectively), resulting in 8,585,792 total clean sequences (274,568 from  
45 Canada). Pango lineages in the metadata were called using pangolin v3.1.20 and pangoLEARN  
46 data release March 22, 2022 (5, 6).

1  
2 Total clean sequences available were grouped by variant (**Table S3**): Alpha (B.1.1.7, Q.\*), Beta  
3 (B.1.351), Gamma (P.1), Delta (B.1.617.2, AY.\*), Epsilon (B.1.429 and B.1.427), Zeta (P.2), Eta  
4 (B.1.525), Iota (B.1.526), Kappa (B.1.617.1), Mu (B.1.621), and Omicron (separately: BA.1,  
5 BA.1.1, and BA.2). Any sequence not identified as a variant was grouped into ‘Other’. Variants  
6 with fewer than 100 sequences from Canada were excluded (Lambda, Theta, GH/490R, and BA.3).  
7 The primary manuscript focuses on the five VOCs, Alpha, Beta, Gamma, Delta, and Omicron  
8 BA.1, BA.1.1, and BA.2, for which there were targeted travel restrictions. Omicron was split into  
9 its comprising Pango lineages as their spatiotemporal origins into Canada differed. The earliest  
10 global sample collection dates for each variant were obtained from cov-lineages.org (45) and  
11 outbreak.info (46) and earliest Canadian dates were pulled from clean GISAID data (**Table S1**).  
12 Canadian sequences with collection dates preceding the earliest global date for each variant were  
13 removed.

14

### 15 **Estimating variant-specific cases by Canadian province and global region**

16 Canadian daily new COVID-19 diagnoses by province were obtained from the Public Health  
17 Agency of Canada (47). Global daily new diagnoses by country were obtained from the R package  
18 coronavirus (48), which pulls data from the Johns Hopkins University Center for Systems Science  
19 and Engineering Coronavirus repository. Rolling 7-day averages of daily new diagnoses were  
20 calculated to smooth the data. For global regions, countries were grouped into continents unless  
21 their sequence contributions were within the top 95<sup>th</sup> percentile, which included Brazil, Denmark,  
22 France, Germany, India, Japan, South Africa, Spain, Sweden, Switzerland, UK, and USA.

23

24 Average daily variant-specific cases in Canadian provinces and global regions were calculated as  
25 the product of average daily new diagnoses and average daily variant frequency based on clean  
26 GISAID sequences (**Figs. S4, S6**). Total monthly contributions to variant-specific cases were  
27 calculated for each province and global regions, then tallies were grouped by variant to calculate  
28 geographies’ proportional contributions to cases of each variant for each calendar month (**Fig. S5,**  
29 **S7**). Monthly proportional contributions of each geography to variant-specific cases were used to  
30 inform the probability of subsampling a sequence from a given geography and month.

31

### 32 **Subsampling data to reduce spatiotemporal bias**

33 For each of ten bootstraps, 50,000 sequences were subsampled where possible, including 50%  
34 sampled in Canada and 50% sampled globally, which was identified as an optimal split of  
35 sequences in previous subsampling sensitivity analyses (4). The temporal distribution of sampled  
36 sequences reflected the distribution of monthly estimated variant-specific cases for Canada and  
37 global regions, respectively (**Fig. S8**). If there were fewer sequences available than the target of  
38 25,000 for a given variant in Canada or global, then all sequences were retained. The proportion  
39 of variant cases occurring in each month was multiplied by the total number of target sequences  
40 to obtain monthly targets. If fewer sequences were available in any given month than the target,  
41 then all sequences from that month were taken. If the target sequences for a given month were  
42 available, but sparse (fewer than 500) during the first half of the months where sequences are  
43 available, then the number of target sequences was specified as 500 (**Fig. S8**). Remaining  
44 sequences were redistributed among months where there were not sparse sequences, and the loop  
45 repeated until there were no sparse months and the target number of sequences sampled was



1 achieved. Relative frequencies of variant cases, sequences available (**Table S3**), and sequences  
2 sampled (**Figs. S10, S11**) were summarized.

3  
4 A small number of sequences were additionally included in each sample set from all parental  
5 lineages basal to variants, i.e. for B.1.1.7, sequences were included from lineages B, B.1, and  
6 B.1.1. For B, Wuhan-hu-1 was sampled; and for other parental lineages, ten sequences with a  
7 collection date preceding that of first global sample for the variant were sampled at random from  
8 the global dataset for each bootstrap independently. This was done to provide phylogenetic  
9 structure for early branching events and inform the estimation of the timing of variant emergence.

10  
11 Sequences were subsampled according to the temporal distributions described above, with  
12 probabilities equal to monthly contribution of global regions or Canadian provinces to variant-  
13 specific cases, up to the total number of target sequences per month. Subsampling was repeated  
14 for ten bootstraps with replacement. Similar subsampling approaches based on countries' cases or  
15 deaths have been applied elsewhere (*16, 49*).

16  
17 All 1,752,808 unique subsampled genome sequences from 200 countries and territories were  
18 collated into GISAID EPI\_SET\_230510yr, accessible at doi:10.55876/gis8.230510yr and via the  
19 attached Supplemental Table provided by GISAID. This serves as the data acknowledgement for  
20 all contributing and submitting laboratories. Those without GISAID Access Credentials may  
21 retrieve information about all data contributors by either clicking on the DOI or pasting the  
22 EPI\_SET ID in the "Data Acknowledgement Locator" on the GISAID homepage.

### 23 24 **Maximum likelihood phylogenetic inference and ancestral state reconstruction**

25 Problematic sites were censored from sequence alignments prior to phylogenetic inference  
26 according to de Maio et al. VCFv4.3 (*50*). Approximate maximum likelihood trees were generated  
27 using FastTree v2.1.11 under a generalized time reversible substitution model and the '-fastest'  
28 algorithm (*51*). Trees were outgroup rooted on Wuhan-hu-1 in R package ape (*52*). A linear  
29 regression of root-to-tip distance versus time was generated for each tree, excluding parental  
30 lineage sequences. Tips with absolute value residuals greater than 0.001 or terminal branch lengths  
31 longer than 20 mutations were excluded as temporal outliers. Trees were time-scaled using IQ-  
32 TREE 2.1.2 with least squares dating (LSD2) (*35, 53*), a relaxed molecular clock, 0.2 relative  
33 variance, and 50 bootstrap resamples to estimate internal branch lengths. Polytomies were  
34 randomly resolved.

35  
36 Phylogeographic reconstruction of internal nodes' geographic state as Canadian province or global  
37 region was conducted using maximum likelihood discrete ancestral character estimation in R  
38 package ape with symmetrical rates (*52*). The highest likelihood state was pulled for each internal  
39 node. Canadian sublineages were designated where Canadian internal nodes were preceded by a  
40 non-Canadian internal node, signifying an international introduction resulting in onward sampled  
41 transmission. Singletons were defined as Canadian sequences with non-Canadian parental origin  
42 and no sampled descendants. Sublineage and singleton importation rates were summarized as 7-  
43 day rolling mean of importations per week by global region, province of introduction, and Pango  
44 lineage. The sum of sublineages and singletons represents a lower limit for the total number of  
45 introductions due to subsampling. Rate estimates were reported as the mean across bootstraps,  
46 with 95% confidence intervals calculated using the t-distribution,  $\mu \pm t \times \sigma/\sqrt{n}$ .

1  
2 Summary metrics included the fold-reduction of sublineage and singleton importation rates from  
3 focal sources two weeks after implementation of restrictions versus before, and fold reduction in  
4 proportion of sublineages from focal sources compared to other regions before versus during  
5 restrictions. For either metric, the null hypothesis was that restrictions had no effect on either  
6 importation rates or proportion of importations from the focal source; therefore, if the 95%  
7 confidence intervals do not overlap one, we reject the null hypothesis and have evidence to support  
8 restrictions' effectiveness.

### 9 10 **Estimating cases averted by restrictions**

11 We estimated cases averted due to travel restrictions for each VOC by comparing observed  
12 introduction rates to expectations in the absence of travel restrictions, as predicted from a  
13 mechanistic counterfactual model of the relationship between introduction rates and variant cases  
14 in the focal source, trained on data preceding the intervention. Linear models consistently had the  
15 best goodness-of-fit in comparison with Poisson and negative binomial models. Training data were  
16 restricted to the week preceding the restriction or where variant cases in the source region exceeded  
17 a threshold chosen to maximize the correlation between cases and importations (described for each  
18 VOC in supplementary; **Figs. S23-28**). Observed daily variant cases in the focal source during the  
19 intervention and expected travel volume were used to predict sublineages per week in the absence  
20 of restrictions. Likelihood ratio tests were applied to evaluate inclusion of travel volume as a  
21 covariate; it was included for BA.1.1.

22  
23 Statistics Canada data on international arrivals (54) was used to quantify observed and estimate  
24 expected travel volume from the focal sources in the absence of restrictions based on seasonal and  
25 epochal travel changes (**Supplementary Material**). Areas under curves of observed and predicted  
26 sublineages per week (converted to per day) were calculated to obtain numbers of sublineages  
27 observed and predicted during restrictions, the difference of which equates to sublineages averted.  
28 Sublineages averted was calculated for entire intervention durations and for early and late periods  
29 (**Fig. 4**). For each averted sublineage, sublineage size (number of sampled descendants) was drawn  
30 from VOC-specific gamma distributions fitted to sublineage sizes observed until the end of  
31 restrictions. Cases averted from averted sublineages were summed. This was repeated 1000 times  
32 to estimate a mean number of total descendant cases averted for the mean and confidence limits of  
33 sublineages averted. Confidence intervals were estimated by carrying forward upper and lower  
34 limits of importation rates estimated across bootstraps.

35  
36 The model fitting process was repeated for singletons by fitting models of singletons per week to  
37 variant cases, predicting singletons per week in the absence of restrictions, and taking the  
38 difference in observed and expected singletons to estimate the number of singletons averted. Total  
39 cases averted is the sum of singletons averted and descendant cases from sublineages averted for  
40 each period. The percentage additional cases equals the ratio of total cases averted to total variant  
41 cases in Canada overall. Sublineages, singletons, and cases averted were normalized to days of  
42 restriction duration. Based on the cases averted and variant-specific hospitalization and death rates  
43 in Canada for each variant, we roughly estimated averted hospitalizations, healthcare costs, and  
44 deaths.

### 45 46 **Economic estimations**

1 To approximate health care cost savings attributable to travel restrictions, we translated cases  
2 averted to COVID-19 hospitalizations, intensive care unit (ICU) visits, and deaths. Based on a  
3 literature search for case hospitalization rates, we assumed an average 1% hospitalization rate  
4 throughout the study period, as estimated for the USA between May 2020 and April 2021 of 1093.9  
5 hospitalizations per 100,000 cases (1.1%) (17). The average costs of \$15,000 for a COVID-19  
6 hospitalization in Canada not in ICU and \$55,000 for those admitted to ICU were obtained from  
7 the Canadian Institutes for Health Information (CIHI) (18). We also assume CIHI estimates that  
8 21% of COVID-19 hospitalizations resulted in ICU admission, and that 56% of ICU patients  
9 received ventilation and 25% died in the facility (18).

## 11 References

- 13 1. F. Konings, M. D. Perkins, J. H. Kuhn, M. J. Pallen, E. J. Alm, B. N. Archer, A. Barakat, T.  
14 Bedford, J. N. Bhiman, L. Caly, L. L. Carter, A. Cullinane, T. de Oliveira, J. Druce, I. E. Masry,  
15 R. Evans, G. F. Gao, A. E. Gorbalenya, E. Hamblion, B. L. Herring, E. Hodcroft, E. C. Holmes,  
16 M. Kakkar, S. Khare, M. P. G. Koopmans, B. Korber, J. Leite, D. MacCannell, M. Marklewitz,  
17 S. Maurer-Stroh, J. A. M. Rico, V. J. Munster, R. Neher, B. O. Munnink, B. I. Pavlin, M. Peiris,  
18 L. Poon, O. Pybus, A. Rambaut, P. Resende, L. Subissi, V. Thiel, S. Tong, S. van der Werf, A.  
19 von Gottberg, J. Ziebuhr, M. D. V. Kerkhove, SARS-CoV-2 Variants of Interest and Concern  
20 naming scheme conducive for global discourse. *Nat. Microbiol.* **6**, 821–823 (2021). doi: s41564-  
21 021-00932-w.
- 22 2. M. Worobey, J. Pekar, B. B. Larsen, M. I. Nelson, V. Hill, J. B. Joy, A. Rambaut, M. A.  
23 Suchard, J. O. Wertheim, P. Lemey, The emergence of SARS-CoV-2 in Europe and North  
24 America. *Science*. **370**, 564–570 (2020). doi: 10.1126/science.abc8169.
- 25 3. L. du Plessis, J. T. McCrone, A. E. Zarebski, V. Hill, C. Ruis, B. Gutierrez, J. Raghvani, J.  
26 Ashworth, R. Colquhoun, T. R. Connor, N. R. Faria, B. Jackson, N. J. Loman, Á. O’Toole, S. M.  
27 Nicholls, K. V. Parag, E. Scher, T. I. Vasylyeva, E. M. Volz, A. Watts, I. I. Bogoch, K. Khan,  
28 C.-19 G. U. (COG-U. Consortium†, D. M. Aanensen, M. U. G. Kraemer, A. Rambaut, O. G.  
29 Pybus, Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK. *Science*.  
30 **371**, 708–712 (2021). doi: 10.1126/science.abf2946.
- 31 4. A. McLaughlin, V. Montoya, R. L. Miller, G. J. Mordecai, C. C.-19 G. N. (CanCOGen)  
32 Consortium, M. Worobey, A. F. Poon, J. B. Joy, Genomic epidemiology of the first two waves  
33 of SARS-CoV-2 in Canada. *Elife*. **11**, e73896 (2022). doi: 10.7554/eLife.73896.
- 34 5. A. Rambaut, E. C. Holmes, Á. O’Toole, V. Hill, J. T. McCrone, C. Ruis, L. du Plessis, O. G.  
35 Pybus, A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic  
36 epidemiology. *Nat. Microbiol.* **5**, 1–7 (2020). doi: 10.1038/s41564-020-0770-5.
- 37 6. Á. O’Toole, V. Hill, O. G. Pybus, A. Watts, I. I. Bogoch, K. Khan, J. P. Messina, T. COVID-  
38 19 Genomics UK (COG-UK) consortium, Network for Genomic Surveillance in South Africa  
39 (NGS-SA), Brazil-UK CADDE Genomic Network, H. Tegally, R. R. Lessells, J. Giandhari, S.  
40 Pillay, K. A. Tumedi, G. Nyepetsi, M. Kebabonye, M. Matsheka, M. Mine, S. Tokajian, H.

- 1 Hassan, T. Salloum, G. Merhi, J. Koweyes, J. L. Geoghegan, J. de Ligt, X. Ren, M. Storey, N. E.  
2 Freed, C. Pattabiraman, P. Prasad, A. S. Desai, R. Vasanthapuram, T. F. Schulz, L. Steinbrück,  
3 T. Stadler, S. V. S. Consortium, A. Parisi, A. Bianco, D. G. de Viedma, S. Buenestado-Serrano,  
4 V. Borges, J. Isidro, S. Duarte, J. P. Gomes, N. S. Zuckerman, M. Mandelboim, O. Mor, T.  
5 Seemann, A. Arnott, J. Draper, M. Gall, W. Rawlinson, I. Deveson, S. Schlebusch, J. McMahon,  
6 L. Leong, C. K. Lim, M. Chironna, D. Loconsole, A. Bal, L. Josset, E. Holmes, K. S. George, E.  
7 Lasek-Nesselquist, R. S. Sikkema, B. O. Munnink, M. Koopmans, M. Brytting, V. S. rani, S.  
8 Pavani, T. Smura, A. Heim, S. Kurkela, M. Umair, M. Salman, B. Bartolini, M. Rueca, C.  
9 Drosten, T. Wolff, O. Silander, D. Eggink, C. Reusken, H. Vennema, A. Park, C. Carrington, N.  
10 Sahadeo, M. Carr, G. Gonzalez, Search Alliance San Diego, National Virus Reference  
11 Laboratory, SeqCOVID-Spain, Danish Covid-19 Genome Consortium (DCGC), Communicable  
12 Diseases Genomic Network (CDGN), Dutch National SARS-CoV-2 surveillance program,  
13 Division of Emerging Infectious Disease (KDCA), T. de Oliveira, N. Faria, A. Rambaut, M. U.  
14 G. Kraemer, Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and  
15 B.1.351/501Y-V2 with grinch. *Wellcome Open Res.* **6**, 121 (2021). doi:  
16 10.12688/wellcomeopenres.16661.2.
- 17 7. J. Hadfield, C. Megill, S. M. Bell, J. Huddleston, B. Potter, C. Callender, P. Sagulenko, T.  
18 Bedford, R. A. Neher, Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics.* **23**,  
19 62–3 (2018). doi: 10.1093/bioinformatics/bty407.
- 20 8. S. A. Nadeau, T. G. Vaughan, C. Beckmann, I. Topolsky, C. Chen, E. Hodcroft, T. Schär, I.  
21 Nissen, N. Santacroce, E. Burcklen, P. Ferreira, K. P. Jablonski, S. Posada-Céspedes, V. Capece,  
22 S. Seidel, N. S. de Souza, J. M. Martinez-Gomez, P. Cheng, P. P. Bosshard, M. P. Levesque, V.  
23 Kufner, S. Schmutz, M. Zaheri, M. Huber, A. Trkola, S. Cordey, F. Laubscher, A. R. Gonçalves,  
24 S. Aeby, T. Pilonel, D. Jacot, C. Bertelli, G. Greub, K. Leuzinger, M. Stange, A. Mari, T.  
25 Roloff, H. Seth-Smith, H. H. Hirsch, A. Egli, M. Redondo, O. Kobel, C. Noppen, L. du Plessis,  
26 N. Beerenwinkel, R. A. Neher, C. Beisel, T. Stadler, Swiss public health measures associated  
27 with reduced SARS-CoV-2 transmission using genome data. *Sci. Transl. Med.* (2022), doi:  
28 10.1101/2021.11.11.21266107.
- 29 9. N. Anderegg, T. Schwab, L. Borcard, C. Mugglin, B. Keune-Dübi, A. Ramette, L. Fenner,  
30 Population-based SARS-CoV-2 whole genome sequencing and contact tracing during the  
31 COVID-19 pandemic in Switzerland. *J. Infect. Dis.* **27**, jiad074 (2023). doi:  
32 10.1093/infdis/jiad074.
- 33 10. J. Douglas, F. K. Mendes, R. Bouckaert, D. Xie, C. L. Jiménez-Silva, C. Swanepoel, J. de  
34 Ligt, X. Ren, M. Storey, J. Hadfield, C. R. Simpson, J. L. Geoghegan, A. J. Drummond, D.  
35 Welch, Phylodynamics Reveals the Role of Human Travel and Contact Tracing in Controlling  
36 the First Wave of COVID-19 in Four Island Nations. *Virus Evol.* **7**, (2021). doi:  
37 10.1093/ve/veab052.
- 38 11. N. Banholzer, A. Lison, D. Özcelik, T. Stadler, S. Feuerriegel, W. Vach, The methodologies  
39 to assess the effectiveness of non-pharmaceutical interventions during COVID-19: a systematic  
40 review. *Eur. J. Epidemiol.* **37**, 1003–1024 (2022). doi: 10.1007/s10654-022-00908-y.

- 1 12. A. Lison, N. Banholzer, M. Sharma, S. Mindermann, H. J. T. Unwin, S. Mishra, T. Stadler,  
2 S. Bhatt, N. M. Ferguson, J. Brauner, W. Vach, Effectiveness assessment of non-pharmaceutical  
3 interventions: lessons learned from the COVID-19 pandemic. *Lancet Public Heal.* **8**, e311–e317  
4 (2023). doi: 10.1016/S2468-2667(23)00046-4.
- 5 13. T. I. Vasylyeva, C. E. Fang, M. Su, J. L. Havens, E. Parker, J. C. Wang, M. Zeller, A.  
6 Yakovleva, G. W. Hassler, M. A. Chowdhury, K. G. Andersen, S. Hughes, J. O. Wertheim,  
7 Introduction and Establishment of SARS-CoV-2 Gamma Variant in New York City in Early  
8 2021. *J. Infect. Dis.* **226**(12), 2142-2149J (2022). doi: 10.1093/infdis/jiac265.
- 9 14. A. Henschel, S. F. Feng, R. A. Hamoudi, G. D. Elbait, E. Damiani, F. Waasia, G. K. Tay, B.  
10 H. Mahboub, M. H. Uddin, J. Acuna, E. Alefishat, R. Halwani, H. F. Jelinek, F. Mustafa, N.  
11 Alkaabi, H. S. Alsafar, U. C.-19 C. Partnership, Travel ban effects on SARS-CoV-2 transmission  
12 lineages in the UAE as inferred by genomic epidemiology. *PLoS One.* **17**, e0264682 (2022). doi:  
13 10.1371/journal.pone.0264682.
- 14 15. H. Gu, R. Xie, D. C. Adam, J. L.-H. Tsui, D. K. Chu, L. D. J. Chang, S. S. Y. Cheuk, S.  
15 Gurung, P. Krishnan, D. Y. M. Ng, G. Y. Z. Liu, C. K. C. Wan, S. S. M. Cheng, K. M. Edwards,  
16 K. S. M. Leung, J. T. Wu, D. N. C. Tsang, G. M. Leung, B. J. Cowling, M. Peiris, T. T. Y. Lam,  
17 V. Dhanasekaran, L. L. M. Poon, Genomic epidemiology of SARS-CoV-2 under an elimination  
18 strategy in Hong Kong. *Nat Commun.* **13**, 736 (2022). doi: 10.1038/s41467-022-28420-7.
- 19 16. H. Tegally, E. Wilkinson, J. L.-H. Tsui, M. Moir, D. Martin, A. F. Brito, M. Giovanetti, K.  
20 Khan, C. Huber, I. I. Bogoch, J. E. San, J. Poongavanan, J. S. Xavier, D. da S. Candido, F.  
21 Romero, C. Baxter, O. G. Pybus, R. Lessells, N. R. Faria, M. U. G. Kraemer, T. de Oliveira,  
22 Dispersal Patterns and Influence of Air Travel During the Global Expansion of SARS-CoV-2  
23 Variants of Concern. *Cell.* **186**(15), 3277-3290.e16. (2023). doi: 10.1016/j.cell.2023.06.001.
- 24 17. A. Couture, A. D. Iuliano, H. H. Chang, N. N. Patel, M. Gilmer, M. Steele, F. P. Havers, M.  
25 Whitaker, C. Reed, Estimating COVID-19 Hospitalizations in the United States With  
26 Surveillance Data Using a Bayesian Hierarchical Model: Modeling Study. *JMIR Public Heal.*  
27 *Surveill.* **8**, e34296 (2022). doi: 10.2196/34296.
- 28 18. Canadian Institute for Health Information, COVID-19 hospitalization and emergency  
29 department statistics (2023) [https://www.cihi.ca/en/covid-19-hospitalization-and-emergency-](https://www.cihi.ca/en/covid-19-hospitalization-and-emergency-department-statistics)  
30 [department-statistics](https://www.cihi.ca/en/covid-19-hospitalization-and-emergency-department-statistics).
- 31 19. C. L. Murall, R. Poujol, S. A. Kraemer, A. Zetner, A. Pekau, B. Sobkowiak, E. Gill, A.  
32 N'Guessan, S. Naderia, J. Fritz, F. Brinkman, J. Hussin, C. Colijn, G. V. Domselaar, S. P. Otto,  
33 B. J. Shapiro, T. C. C.-19 G. N. (CanCOGeN), Monitoring the growth and evolution of Delta  
34 sublineages AY.25 and AY.27 in Canada. *Virological.org* [Preprint] (2021)  
35 [https://virological.org/t/monitoring-the-evolution-and-spread-of-delta-sublineages-ay-25-and-ay-](https://virological.org/t/monitoring-the-evolution-and-spread-of-delta-sublineages-ay-25-and-ay-27-in-canada/767)  
36 [27-in-canada/767](https://virological.org/t/monitoring-the-evolution-and-spread-of-delta-sublineages-ay-25-and-ay-27-in-canada/767).

- 1 20. W. S. Hart, E. Miller, N. J. Andrews, P. Waight, P. K. Maini, S. Funk, R. N. Thompson,  
2 Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis.  
3 *Lancet Infect. Dis.* **22**(5), 603-610, (2022). doi: 10.1016/s1473-3099(22)00001-9.
- 4 21. L. Jelley, J. Douglas, X. Ren, D. Winter, A. McNeill, S. Huang, N. French, D. Welch, J.  
5 Hadfield, J. de Ligt, J. L. Geoghegan, Genomic epidemiology of Delta SARS-CoV-2 during  
6 transition from elimination to suppression in Aotearoa New Zealand. *Nat. Commun.* **13**, 4035  
7 (2022). doi: 10.1038/s41467-022-31784-5.
- 8 22. D. Planas, D. Veyer, A. Baidaliuk, I. Staropoli, F. Guivel-Benhassine, M. M. Rajah, C.  
9 Planchais, F. Porrot, N. Robillard, J. Puech, M. Prot, F. Gallais, P. Gantner, A. Velay, J. L. Guen,  
10 N. Kassis-Chikhani, D. Edriss, L. Belec, A. Seve, L. Courtellemont, H. Péré, L. Hocqueloux, S.  
11 Fafi-Kremer, T. Prazuck, H. Mouquet, T. Bruel, E. Simon-Lorière, F. A. Rey, O. Schwartz,  
12 Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature.* **596**, 276–  
13 280 (2021). doi: 10.1038/s41586-021-03777-9.
- 14 23. S. Talic, S. Shah, H. Wild, D. Gasevic, A. Maharaj, Z. Ademi, X. Li, W. Xu, I. Mesa-  
15 Eguiagaray, J. Rostron, E. Theodoratou, X. Zhang, A. Motee, D. Liew, D. Ilic, Effectiveness of  
16 public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and  
17 covid-19 mortality: systematic review and meta-analysis. *BMJ.* **375**, e068302 (2021). doi:  
18 10.1136/bmj-2021-068302.
- 19 24. T. Mashe, F. T. Takawira, L. de O. Martins, M. Gudza-Mugabe, J. Chirenda, M. Munyanyi,  
20 B. V. Chaibva, A. Tarupiwa, H. Gumbo, A. Juru, C. Nyagupe, V. Ruhanya, I. Phiri, P.  
21 Manangazira, A. Goredema, S. Danda, I. Chabata, J. Jonga, R. Munharira, K. Masunda, I.  
22 Mukeredzi, D. Mangwanya, A. Trotter, T. L. Viet, S. Rudder, G. Kay, D. Baker, G. Thilliez, A.  
23 V. Gutierrez, J. O’Grady, M. Hove, S. Mutapuri-Zinyowera, A. J. Page, R. A. Kingsley, G.  
24 Mhlanga, COVID-19 Genomics UK Consortium, SARS-CoV-2 Research Group, Genomic  
25 epidemiology and the role of international and regional travel in the SARS-CoV-2 epidemic in  
26 Zimbabwe: a retrospective study of routinely collected surveillance data. *Lancet Global Heal.* **9**,  
27 e1658–e1666 (2021). doi: 10.1016/S2214-109X(21)00434-4.
- 28 25. J.-H. Kwon, J.-M. Kim, D. Lee, A. K. Park, I.-H. Kim, D.-W. Kim, J.-Y. Kim, N. Lim, K.-Y.  
29 Cho, H. M. Kim, N.-J. Lee, S. Woo, C. Y. Lee, J. S. No, J. Kim, J. Rhee, M.-G. Han, G.-E. Rhie,  
30 C. K. Yoo, E.-J. Kim, Genomic epidemiology reveals the reduction of the introduction and  
31 spread of SARS-CoV-2 after implementing control strategies in Republic of Korea, 2020. *Virus*  
32 *Evol.* **7**, veab077 (2021). doi: 10.1093/ve/veab077.
- 33 26. J. T. McCrone, V. Hill, S. Bajaj, R. E. Pena, B. C. Lambert, R. Inward, S. Bhatt, E. Volz, C.  
34 Ruis, S. Dellicour, G. Baele, A. E. Zarebski, A. Sadilek, N. Wu, A. Schneider, X. Ji, J.  
35 Raghwani, B. Jackson, R. Colquhoun, Á. O’Toole, T. P. Peacock, K. Twohig, S. Thelwall, G.  
36 Dabrera, R. Myers, T. COVID-19 Genomics UK (COG-UK) Consortium, N. R. Faria, C. Huber,  
37 I. I. Bogoch, K. Khan, L. du Plessis, J. C. Barrett, D. M. Aanensen, W. S. Barclay, M. Chand, T.  
38 Connor, N. J. Loman, M. A. Suchard, O. G. Pybus, A. Rambaut, M. U. G. Kraemer, Context-  
39 specific emergence and growth of the SARS-CoV-2 Delta variant. *Nature.* **610**, 154–160 (2022).  
40 doi: 10.1038/s41586-022-05200-3.

- 1 27. R. Viana, S. Moyo, D. G. Amoako, H. Tegally, C. Scheepers, C. L. Althaus, U. J. Anyaneji,  
2 P. A. Bester, M. F. Boni, M. Chand, W. T. Choga, R. Colquhoun, M. Davids, K. Deforche, D.  
3 Doolabh, L. du Plessis, S. Engelbrecht, J. Everatt, J. Giandhari, M. Giovanetti, D. Hardie, V.  
4 Hill, N.-Y. Hsiao, A. Iranzadeh, A. Ismail, C. Joseph, R. Joseph, L. Koopile, S. L. K. Pond, M.  
5 U. G. Kraemer, L. Kuate-Lere, O. Laguda-Akingba, O. Lesetedi-Mafoko, R. J. Lessells, S.  
6 Lockman, A. G. Lucaci, A. Maharaj, B. Mahlangu, T. Maponga, K. Mahlakwane, Z. Makatini,  
7 G. Marais, D. Maruapula, K. Masupu, M. Matshaba, S. Mayaphi, N. Mbhele, M. B. Mbulawa, A.  
8 Mendes, K. Mlisana, A. Mnguni, T. Mohale, M. Moir, K. Moruisi, M. Mosepele, G. Motsatsi,  
9 M. S. Motswaledi, T. Mphoyakgosi, N. Msomi, P. N. Mwangi, Y. Naidoo, N. Ntuli, M. Nyaga,  
10 L. Olubayo, S. Pillay, B. Radibe, Y. Ramphal, U. Ramphal, J. E. San, L. Scott, R. Shapiro, L.  
11 Singh, P. Smith-Lawrence, W. Stevens, A. Strydom, K. Subramoney, N. Tebeila, D. Tshiabuila,  
12 J. Tsui, S. van Wyk, S. Weaver, C. K. Wibmer, E. Wilkinson, N. Wolter, A. E. Zarebski, B.  
13 Zuze, D. Goedhals, W. Preiser, F. Treurnicht, M. Venter, C. Williamson, O. G. Pybus, J.  
14 Bhiman, A. Glass, D. P. Martin, A. Rambaut, S. Gaseitsiwe, A. von Gottberg, T. de Oliveira,  
15 Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. *Nature*. **603**,  
16 679–686 (2022). doi: 10.1038/s41586-022-04411-y.
- 17 28. Government of Canada, Current travel restrictions—Standing Committee on Health:  
18 Emergency Situation Facing Canadians in Light of the COVID-19 Pandemic (2021),  
19 [https://www.cbsa-asfc.gc.ca/transparency-transparence/pd-dp/bbp-rpp/hesa/2021-05-](https://www.cbsa-asfc.gc.ca/transparency-transparence/pd-dp/bbp-rpp/hesa/2021-05-21/travrestrict-restrictvoya-eng.html)  
20 [21/travrestrict-restrictvoya-eng.html](https://www.cbsa-asfc.gc.ca/transparency-transparence/pd-dp/bbp-rpp/hesa/2021-05-21/travrestrict-restrictvoya-eng.html).
- 21 29. British Columbia COVID-19 Modelling Group, COVID Model Projections February 4, 2022  
22 (2022). <https://bccovid-19group.ca/>
- 23 30. P. Liu, Y. Song, C. Colijn, A. MacPherson, The impact of sampling bias on viral  
24 phylogeographic reconstruction. *PLOS Global Public Heal.* **2**, e0000577 (2022). doi:  
25 10.1371/journal.pgph.0000577.
- 26 31. P. Lemey, S. L. Hong, V. Hill, G. Baele, C. Poletto, V. Colizza, Á. O’Toole, J. T. McCrone,  
27 K. G. Andersen, M. Worobey, M. I. Nelson, A. Rambaut, M. A. Suchard, Accommodating  
28 individual travel history and unsampled diversity in Bayesian phylogeographic inference of  
29 SARS-CoV-2. *Nature Communications*. **11**, 1–14 (2020). doi: 10.1038/s41467-020-18877-9.
- 30 32. C. Colijn, D. J. Earn, J. Dushoff, N. H. Ogden, M. Li, N. Knox, G. V. Domselaar, K.  
31 Franklin, G. Jolly, S. P. Otto, The need for linked genomic surveillance of SARS-CoV-2. *Can.*  
32 *Commun. Dis. Rep.* **48**, 131–139 (2022). doi: 10.14745/ccdr.v48i04a03.
- 33 33. S. Mishra, J. D. Walker, L. Wilhelm, V. Larivière, T. Bubela, S. E. Straus, Use and misuse of  
34 research: Canada’s response to COVID-19 and its health inequalities. *BMJ*. **382**, e075666  
35 (2023). doi: 10.1136/bmj-2023-075666.
- 36 34. T. Bubela, C. M. Flood, K. McGrail, S. E. Straus, S. Mishra, How Canada’s decentralised  
37 covid-19 response affected public health data and decision making. *BMJ*. **382**, e075665 (2023).  
38 doi: 10.1136/bmj-2023-075665.

- 1 35. T. H. To, M. Jung, S. Lycett, O. Gascuel, Fast dating using least-squares criteria and  
2 algorithms. *Systematic Biology*. **65**, 82–97 (2016). doi: 10.1093/sysbio/syv068.
- 3 36. S. P. Otto, T. Day, J. Arino, C. Colijn, J. Dushoff, M. Li, S. Mechai, G. V. Domselaar, J. Wu,  
4 D. J. D. Earn, N. H. Ogden, The origins and potential future of SARS-CoV-2 variants of concern  
5 in the evolving COVID-19 pandemic. *Curr Biol*. **31**, R918–R929 (2021). doi:  
6 10.1016/j.cub.2021.06.049.
- 7 37. M. D. Figgins, T. Bedford, SARS-CoV-2 variant dynamics across US states show consistent  
8 differences in effective reproduction numbers, *Medrxiv* [Preprint] (2022) doi:  
9 10.1101/2021.12.09.21267544.
- 10 38. J. E. Stockdale, P. Liu, C. Colijn, The potential of genomics for infectious disease  
11 forecasting. *Nat. Microbiol*. **7**, 1736–1743 (2022). doi: 10.1038/s41564-022-01233-6.
- 12 39. K. Koelle, M. A. Martin, R. Antia, B. Lopman, N. E. Dean, The changing epidemiology of  
13 SARS-CoV-2. *Science*. **375**, 1116–1121 (2022). doi: 10.1126/science.abm4915.
- 14 40. Y. Shu, J. McCauley, GISAID: Global initiative on sharing all influenza data – from vision  
15 to reality. *Eurosurveillance*. **22**, 30494 (2017). doi: 10.2807/1560-7917.ES.2017.22.13.30494.
- 16 41. S. Khare, C. Gurry, L. Freitas, M. B. Schultz, G. Bach, A. Diallo, N. Akite, J. Ho, R. T. Lee,  
17 W. Yeo, GISAID Core Curation Team, S. Maurer-Stroh, GISAID’s Role in Pandemic Response.  
18 *China CDC Wkly*. **3**, 1049–1051 (2021). doi: 10.46234/ccdcw2021.255.
- 19 42. T. Bedford, nextstrain/ncov (2021), <https://github.com/nextstrain/ncov>.
- 20 43. N. Moshiri, ViralMSA: Massively scalable reference-guided multiple sequence alignment of  
21 viral genomes. *Bioinformatics*. **37**, 714–716 (2020). doi: 10.1093/bioinformatics/btaa743.
- 22 44. H. Li, Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics*. **34**, 3094–  
23 3100 (2018). doi: 10.1093/bioinformatics/bty191.
- 24 45. Á. O’Toole, E. Scher, A. Underwood, B. Jackson, V. Hill, J. T. McCrone, R. Colquhoun, C.  
25 Ruis, K. Abu-Dahab, B. Taylor, C. Yeats, L. D. Plessis, D. Maloney, N. Medd, S. W. Attwood,  
26 D. M. Aanensen, E. C. Holmes, O. G. Pybus, A. Rambaut, Assignment of Epidemiological  
27 Lineages in an Emerging Pandemic Using the Pangolin Tool. *Virus Evol*. **7**(2), veab064- (2021).  
28 doi: 10.1093/ve/veab064.
- 29 46. K. Gangavarapu, A. A. Latif, J. L. Mullen, M. Alkuzweny, E. Hufbauer, G. Tsueng, E. Haag,  
30 M. Zeller, C. M. Aceves, K. Zaiets, M. Cano, X. Zhou, Z. Qian, R. Sattler, N. L. Matteson, J. I.  
31 Levy, R. T. C. Lee, L. Freitas, S. Maurer-Stroh, GISAID Core and Curation Team, M. A.  
32 Suchard, C. Wu, A. I. Su, K. G. Andersen, L. D. Hughes, Outbreak.info genomic reports:  
33 scalable and dynamic surveillance of SARS-CoV-2 variants and mutations. *Nat. Methods*. **20**,  
34 512–522 (2023). doi: 10.1038/s41592-023-01769-3.



- 1 47. Public Health Agency of Canada, “Coronavirus disease 2019 (COVID-19): Epidemiology  
2 update” (Government of Canada, Ottawa, ON, 2021), [https://health-infobase.canada.ca/covid-  
3 19/epidemiological-summary-covid-19-cases.html?stat=num&;measure=active#a2](https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html?stat=num&;measure=active#a2).
- 4 48. R. Krispin, J. Byrnes, coronavirus: The 2019 Novel Coronavirus COVID-19 (2019-nCoV)  
5 Dataset. R package version 0.3.0. <https://github.com/RamiKrispin/coronavirus> (2020);  
6 <https://cran.r-project.org/web/packages/coronavirus/coronavirus.pdf>.
- 7 49. S. A. Nadeau, T. G. Vaughan, J. Scire, J. S. Huisman, T. Stadler, The origin and early spread  
8 of SARS-CoV-2 in Europe. *Proc. National Acad. Sci.* **118**, e2012008118 (2021). doi:  
9 10.1073/pnas.2012008118.
- 10 50. N. de Maio, C. Walker, R. Borges, L. Weilguny, G. Slodkowitz, N. Goldman, Masking  
11 strategies for SARS-CoV-2 alignments. *virological.org [Preprint]*. (2020).  
12 [virological.org/t/masking-strategies-for-sars-cov-2-alignments/480](https://virological.org/t/masking-strategies-for-sars-cov-2-alignments/480).
- 13 51. M. N. Price, P. S. Dehal, A. P. Arkin, FastTree 2--approximately maximum-likelihood trees  
14 for large alignments. *PLoS ONE*. **5**, e9490 (2010). doi: 10.1371/journal.pone.0009490.
- 15 52. E. Paradis, K. Schliep, ape 5.0: an environment for modern phylogenetics and evolutionary  
16 analyses in R. *Bioinformatics*. **35**, 526–528 (2018). doi: 10.1093/bioinformatics/bty633.
- 17 53. B. Q. Minh, H. A. Schmidt, O. Chernomor, D. Schrempf, M. D. Woodhams, A. von  
18 Haeseler, R. Lanfear, IQ-TREE 2: New Models and Efficient Methods for Phylogenetic  
19 Inference in the Genomic Era. *Molec. Biol. and Evol.* **37**, 1530–1534 (2020). doi:  
20 10.1093/molbev/msaa015.
- 21 54. Statistics Canada, Table 24-10-0056-01 Leading indicator, International visitors entering or  
22 returning to Canada by air, by country of residence and traveller type (2023),  
23 <https://doi.org/10.25318/2410005601-eng>.

24

## 25 **Acknowledgments:**

26 We gratefully acknowledge all originating and submitting laboratories of SARS-CoV-2 genome  
27 sequences and metadata on GISAID. We also thank members of the Canadian COVID-19  
28 Genomics Network (CanCOGeN) Consortium (**Supplementary file of contributions**) and the  
29 Canadian Public Health Laboratory Network (CPHLN) for their contributions towards publicly  
30 available data.

31

## 32 **Funding:**

33 AM was supported by a Canada Graduate Scholarship Doctoral Award from the Canadian  
34 Institutes for Health Research.

35 AM, VM, RLM, and JBJ received funding from the British Columbia Centre for Excellence in  
36 HIV/AIDS and Providence Healthcare.

1 MW was supported by funding from the Centers of Excellence for Influenza Research and  
2 Response (CEIRR).

3 JBJ was supported by an operating grant from the Canadian Institutes of Health Research  
4 Coronavirus Rapid Response Programme grant number 440371 and a Canadian Institutes for  
5 Health Research Variant of Concern Grant.

6

7 **Author contributions:**

8 Conceptualization: AM, JBJ.

9 Methodology: AM, VM, JBJ

10 Investigation: AM

11 Visualization: AM

12 Funding acquisition: AM, JBJ

13 Project administration: JBJ

14 Supervision: JBJ

15 Writing – original draft: AM, JBJ

16 Writing – review & editing: AM, VM, RLM, MW, JBJ

17

18 **Competing interests:** The authors declare no competing interests.

19

20 **Data and materials availability:**

21 Viral genome sequences analyzed in this study were sourced from the Global initiative on  
22 sharing all influenza data (GISAID) coronavirus (CoV) database and are subject to the GISAID  
23 EpiFlu Database Access Agreement. Within this agreement, we cannot distribute data to any  
24 third part other than Authorized Users. A full set of all subsampled genome sequence accession  
25 IDs is available at GISAID EPI\_SET\_230510yr (doi:10.55876/gis8.230510yr), which serves as  
26 the data acknowledgement for all originating and submitting laboratories. Those without  
27 GISAID access credentials may retrieve information about all data contributors by either clicking  
28 on the DOI or pasting the EPI\_SET ID in the "Data Acknowledgement Locator" on the GISAID  
29 homepage. Full and subsampled alignments can be shared to Authorized Users upon request.  
30 Scripts used for data curation, inferences, analyses, and visualization are available at  
31 [github.com/AngMcL/sc2\\_canada\\_variants](https://github.com/AngMcL/sc2_canada_variants).

32

33 **Supplementary materials**

34 Materials and Methods

35 Supplementary Text

36 Figs. S1 to S53

37 Tables S1 to S3

38 References (1-13)